Original paper
Explaining Interpatient Variability in Adalimumab Pharmacokinetics in Patients With Crohn's Disease
Abstract
Background: A significant proportion of patients with Crohn's disease (CD) require dose escalation or fail adalimumab (ADL) therapy over time. ADL, a monoclonal antibody directed against tumor necrosis factor, is approved for treatment of CD. Understanding pharmacokinetics (PK) of ADL is essential to optimize individual dosing in daily practice. The aim of this study was to evaluate PK of ADL in patients with CD and to identify factors that...
Paper Details
Title
Explaining Interpatient Variability in Adalimumab Pharmacokinetics in Patients With Crohn's Disease
Published Date
Apr 1, 2018
Journal
Volume
40
Issue
2
Pages
202 - 211
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History